Skip to main content Skip to search Skip to main navigation
News: Europe

APIC: Publishes Updated “How to Do” Document for GDP for Active Pharmaceutical Ingredients

The Active Pharmaceutical Ingredients Committee (APIC) has published Version 3 of the document “GDP for APIs: How to Do” (June 2026) on its website. The document provides practical guidance on implementing Good Distribution Practice for active pharmaceutical ingredients. 

One change compared with Version 2 of March 2019 is the extension to active pharmaceutical ingredients for veterinary medicinal products. In particular, the document takes into account the requirements of Regulation (EU) 2021/1280 (Good Distribution Practice for Active Pharmaceutical Ingredients used as starting materials for veterinary medicinal products). Furthermore, the regulatory framework has been updated. The scope and numerous explanatory notes have been adapted to allow for the parallel consideration of active substances for human and veterinary medicinal products. Intermediates remain excluded from the scope.

In the main section of the document, which is structured in tabular form, the requirements of the EU GDP Guidelines are compared with the corresponding provisions from the WHO guideline on Good Trade and Distribution Practices for Pharmaceutical Starting Materials, as well as supplementary explanations and practical guidance from APIC. In addition, references are made to ICH Q7 and other relevant guidelines.


Source:

APIC: GDP for APIs: “How to do” Document (PDF)

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

News: EMA

EMA Clarifies Batch Numbering for Parallel-Traded Medicines

EMA updated its GMP/GDP Q&A collection by revising the answer to Question 4 concerning Chapter 5 of the EU GMP Guide. It explains which batch numbers should appear on the packaging of parallel-traded medicines.

Read more
Question of the Week | GMP-Verlag

Why is it Important to use Consistent Microbiological Air Monitoring Methods in Pharmaceutical Cleanrooms?

Here's the answer:
Read more
Cleaning Validation: When PDE Reports and the Worst-Case Selection do not Align

Cleaning Validation: When PDE Reports and the Worst-Case Selection do not Align

Robust PDE reports form the basis of risk-based cleaning validation. This article highlights common deficiencies identified during GMP inspections and explains how they can be avoided.

Read more
News: Europe

EDQM: New Working Party on 3D-printed Medicinal Products

The European Pharmacopoeia Commission (EPC) approved the creation of a working party on 3D-printed medicinal products. Its aim is to support the development of appropriate quality standards in the European Pharmacopoeia (Ph. Eur.).
Read more
EMA: 14 New Nitrosamines for Appendix 1

EMA: 14 New Nitrosamines for Appendix 1

Appendix 1 of EMA’s Questions and Answers on nitrosamine impurities has been updated. This appendix contains acceptable intakes (AIs) established for N-nitrosamines.
Read more
WHO: Draft Revision of its Guidelines on Quality Risk Management

WHO: Draft Revision of its Guidelines on Quality Risk Management

WHO published a revised draft of its “WHO guidelines on quality risk management”. Working document QAS/26.994 is open for public comment until 15 November 2026.
Read more
Previous
Next